Escape Meridian

MIT Technology Review · Mar 20, 2024

MIT Technology Review reports on Insilico’s AI-designed drug candidate

Markdown · JSON · Original source

MIT Technology Review’s article, published March 20, 2024, examines Insilico Medicine’s candidate drug for idiopathic pulmonary fibrosis and the claim that AI helped select both its biological target and chemical structure. Alex Zhavoronkov, Insilico’s co-CEO, says the candidate’s progress through animal testing in 18 months demonstrates that AI can speed drug discovery. The article also describes the candidate’s progress to Phase II trials, which seek initial evidence of whether it helps patients; it does not report that the drug works. The article places that claim against a broader uncertainty: many AI-designed drug candidates are advancing, but the cited BCG analysis could not determine whether they progress faster than conventional drugs, and no AI drugs had completed the journey to approval. It also notes that important failures can occur in later patient tests. Zhavoronkov says the drug may still fail and compares its later development to moving at “the speed of traffic.” The article’s central stake is whether the candidate can help people with a fatal lung disease—not whether AI alone can make that happen. Whether this drug helps patients remains unknown.

Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.

MIT Technology ReviewArticle · technologyreview.comOpen original source

Original source

MIT Technology Review · Article

Source details

Original source date: Mar 20, 2024 (2024-03-20T10:30:00Z).

Date basis: Date from the publisher’s own records, through its API.

Added to Escape Meridian: 2026-11-20T20:23:09.539Z. First observed: 2026-10-28T15:02:06.919Z. Retrieved: 2026-10-28T15:03:52.567Z.

Referenced by

Recorded citations in public readings. A reference alone does not establish agreement or influence.

No public references recorded here yet.

Reference data (JSON)

Limits

Text as retrieved on October 28, 2026; originally published March 20, 2024.

Open question

What evidence will the Phase II trials provide about whether Insilico’s candidate helps patients with idiopathic pulmonary fibrosis?

Source-stated

Zhavoronkov says AI helped Insilico choose both the drug’s target and chemical structure.

AI software not only helped decide what target inside a cell to interact with, but also what the drug’s chemical structure should be.

Source-stated

Zhavoronkov says the candidate’s rapid progress through animal testing demonstrates that AI can make drug discovery faster.

it took 18 months for the compound to be synthesized and complete testing in animals—is a demonstration that AI can make drug discovery faster.

Source-stated

The article says the candidate advanced to Phase II trials, which will seek initial evidence of whether it helps patients.

The drug has since advanced to Phase II trials in China and the U.S., which will seek initial evidence of whether it’s actually helpful to patients

Source-stated

The article says the cited BCG analysis could not determine whether AI-enabled drugs were progressing faster than the conventional pace, and that no AI drugs had completed the journey to approval.

What BCG couldn’t determine was if AI-enabled drugs were progressing more quickly than the conventional pace

Source-stated

Zhavoronkov says the candidate can still fail and that later development will move at the speed of traffic.

“It’s like a Tesla. The initial 0 to 60 is very fast, but after that you are moving at the speed of traffic,” he says. “And you can still fail.”

Source and contributor context

MIT Technology Review · Publisher

The publisher is identified here. No individual author has been inferred.

Source media

Media retrieval status: unchecked.

Terms and references

Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.

Editorial provenance

Version 1. Publication ID: 42fc52ab-29af-fbcf-fc11-3a77d7c14ecc.

Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.

Source check: uncertain by anthropic/claude-opus-5.5 on 2026-11-20T20:18:41.313Z. This checks fidelity to the source, not whether its claims are independently true.

Editorial selection: accept; reasons: bridge_admitted_by_model.

Observation: 23c1c4bc09635a1f34db6362f412fc87a7639ebe0cb56fe00b70e2573637ddc7. Source text hash: d3fee5c2bda2b8df2b91fbe2abaf5e7e65eeb499231265b768f051d2a3006888.

Revision and source-check history

Version 1 · 2026-11-20T20:23:09.539Z

MIT Technology Review reports on Insilico’s AI-designed drug candidate

MIT Technology Review’s article, published March 20, 2024, examines Insilico Medicine’s candidate drug for idiopathic pulmonary fibrosis and the claim that AI helped select both its biological target and chemical structure. Alex Zhavoronkov, Insilico’s co-CEO, says the candidate’s progress through animal testing in 18 months demonstrates that AI can speed drug discovery. The article also describes the candidate’s progress to Phase II trials, which seek initial evidence of whether it helps patients; it does not report that the drug works. The article places that claim against a broader uncertainty: many AI-designed drug candidates are advancing, but the cited BCG analysis could not determine whether they progress faster than conventional drugs, and no AI drugs had completed the journey to approval. It also notes that important failures can occur in later patient tests. Zhavoronkov says the drug may still fail and compares its later development to moving at “the speed of traffic.” The article’s central stake is whether the candidate can help people with a fatal lung disease—not whether AI alone can make that happen. Whether this drug helps patients remains unknown.

Original source

MIT Technology Review · Article

Source details

Original source date: Mar 20, 2024 (2024-03-20T10:30:00Z).

Date basis: Date from the publisher’s own records, through its API.

Added to Escape Meridian: 2026-11-20T20:23:09.539Z. First observed: 2026-10-28T15:02:06.919Z. Retrieved: 2026-10-28T15:03:52.567Z.

Limits

Text as retrieved on October 28, 2026; originally published March 20, 2024.

Open question

What evidence will the Phase II trials provide about whether Insilico’s candidate helps patients with idiopathic pulmonary fibrosis?

Source-stated

Zhavoronkov says AI helped Insilico choose both the drug’s target and chemical structure.

AI software not only helped decide what target inside a cell to interact with, but also what the drug’s chemical structure should be.

Source-stated

Zhavoronkov says the candidate’s rapid progress through animal testing demonstrates that AI can make drug discovery faster.

it took 18 months for the compound to be synthesized and complete testing in animals—is a demonstration that AI can make drug discovery faster.

Source-stated

The article says the candidate advanced to Phase II trials, which will seek initial evidence of whether it helps patients.

The drug has since advanced to Phase II trials in China and the U.S., which will seek initial evidence of whether it’s actually helpful to patients

Source-stated

The article says the cited BCG analysis could not determine whether AI-enabled drugs were progressing faster than the conventional pace, and that no AI drugs had completed the journey to approval.

What BCG couldn’t determine was if AI-enabled drugs were progressing more quickly than the conventional pace

Source-stated

Zhavoronkov says the candidate can still fail and that later development will move at the speed of traffic.

“It’s like a Tesla. The initial 0 to 60 is very fast, but after that you are moving at the speed of traffic,” he says. “And you can still fail.”

Source and contributor context

MIT Technology Review · Publisher

The publisher is identified here. No individual author has been inferred.

Source media

Media retrieval status: unchecked.

Terms and references

Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.

Editorial provenance

Version 1. Publication ID: 42fc52ab-29af-fbcf-fc11-3a77d7c14ecc.

Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.

Source check: uncertain by anthropic/claude-opus-5.5 on 2026-11-20T20:18:41.313Z. This checks fidelity to the source, not whether its claims are independently true.

Editorial selection: accept; reasons: bridge_admitted_by_model.

Observation: 23c1c4bc09635a1f34db6362f412fc87a7639ebe0cb56fe00b70e2573637ddc7. Source text hash: d3fee5c2bda2b8df2b91fbe2abaf5e7e65eeb499231265b768f051d2a3006888.

uncertain · 2026-11-20T20:18:41.313Z · anthropic/claude-opus-5.5

Publication: 42fc52ab-29af-fbcf-fc11-3a77d7c14ecc

attribution — pass: The reading is correctly attributed to MIT Technology Review. It keeps Zhavoronkov's claims as his and the BCG findings as BCG's. The page is a single reported article, not a listing.

Now he says his company, Insilico Medicine, has created the first “true AI drug”

summary — uncertain: The reading leaves out a central contested point: Zhavoronkov's claim that this is the first true AI drug. The article says the claim is impossible to affirm, and Recursion's CEO disputes it. Smallest repair: add one sentence noting the 'first' claim and the pushback. The line 'The article's central stake is whether the candidate can help people...not whether AI alone can make that happen' is unlabeled EM framing that the article does not state. It should be removed or labeled as interpretation. The later-failure point comes from 'Some AI skeptics', not the article's own voice. Otherwise the terms are clear to a general reader.

the nebulous definition of AI makes his claim impossible to affirm

date — pass: March 20, 2024 matches the UTC day of originalPublished. The 2026 retrieval is disclosed and the evidence kind is publisher-page. There is no hindsight framing, and Phase II is reported as ongoing. The 'This summer' CNBC passage and the Deep Dive sidebar may be later or inconsistent additions, but the reading does not rely on them.

support — pass: Each claim's excerpt appears verbatim in the source and supports its claim, with correct attribution to Zhavoronkov or the article. The question about the Phase II evidence follows from the source and does not presume an outcome.

So far, there’s not enough data to say, since no AI drugs have completed the journey to approval.

media — pass: No media is selected and no verified media candidates were supplied.

Challenge or correct this reading

Send a correction or an opposing source with this reading’s URL. Disagreement and uncertainty can remain unresolved.